Language selection

Search

Patent 1050235 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1050235
(21) Application Number: 1050235
(54) English Title: PRODUCTION OF PHARMACEUTICAL BARIUM SULPHATE
(54) French Title: PRODUCTION PHARMACEUTIQUE DU SULFATE DE BARYUM
Status: Term Expired - Post Grant Beyond Limit
Bibliographic Data
Abstracts

English Abstract


PRODUCTION OF PHARMACEUTICAL BARIUM SULPHATE
Abstract of the Disclosure
A new simplified process is described for producing
pharmaceutical barium sulphate in which the barium sulphate
does not require dissolution for purification. The new process
comprises grinding a naturally occurring barite ore containing
individual crystals of substantially pure barium sulphate
together with gangue minerals to form a finely divided
particulate ore material, passing this finely divided ore
through a high intensity wet magnetic separator to remove
magnetic particles, leaving a non-magnetic fraction containing
barium sulphate and low specific gravity minerals, subjecting
the non-magnetic fraction to gravity separation to separate
a substantially pure barium sulphate fraction, leaching the
barium sulphate fraction with sulphuric acid to remove acid
soluble impurities and washing the leached product.


Claims

Note: Claims are shown in the official language in which they were submitted.


THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for producing pharmaceutical barium sul-
phate which comprises grinding a naturally occurring barite
ore containing individual crystals of substantially pure
barium sulphate together with gangue minerals to form a
finely divided particulate ore material having a particle
size of -35 mesh and a minimal amount of fines, passing this
finely divided ore through a high intensity wet magnetic
separator to remove magnetic particles, leaving a non-
magnetic fraction containing barium sulphate and low specific
gravity minerals, subjecting the non-magnetic fraction to
gravity separation to separate a substantially pure barium
sulphate fraction, leaching the barium sulphate fraction
with sulphuric acid to remove acid soluble impurities and
washing the leached product.
2. A process according to claim 1 wherein the gravity
separation is conducted on a wet shaking table.
3. A process according to claim 2 wherein the non-
magnetic fraction separated from the magnetic fraction is
divided into two or more separate fractions based on particle
size range and these fractions are separately subjected to
the gravity separation.
4. A process according to claim 1 wherein the ore
contains a major proportion of barium sulphate together
with minor proportions of gangue materials selected from
iron carbonates, iron oxides, silica and iron silicates.

Description

Note: Descriptions are shown in the official language in which they were submitted.


lns(~ s
Background of the Invention
1. Field of the Invention
This invention relates to a process for producing
a pharmaceutical grade of barium sulphate.
2. Description of the Prior Art
Pharmaceutical barium sulphate is widely used as `~
a radiopaque medium in the gastrointesinal tract, It is a
fine, white, odourless, tasteless bulky powder which is
practically insoluble in water, in organic solvents and
in solutions of acids and of alkalies. It does, however,
exhibit some solubility in hot concentrated sulphuric acid.
; While this extremely inert quality of barium sulPhate makes -~
it ideal as a radiopaque mediu~it has also in the past
created great problems in the production of barium sulphate
of pharmaceutical purity.
s~ The chemical specifications of pharmaceutical
' barium sulPhate are precisely known. The USP specifications
can be summarized as follows:
Test USP Specifications
Heavy Metals (as Pb) 0.0010% maximum
Sulphide To pass test
, Arsenic 0.0001% maximum (As203)
Acid Soluble Substance 0.3% maximum
Soluble Barium Salts To pass test
Phosphate To pass test
Acid or Alkalinity To pass test
The usual commercial procedure now being used
is the Mallinckrodt process in which finely divided barite
ore is taken into solution by means of an acid and then
precipitating barium sulphate. Because of the inertness of
barlum sulphate,this is a very difficult and expensive procedure.

Even the precipitate formed still contains many impurities
and must be sub~ected to a number of additional purification
steps including acid leaching.
It is the object of the present invention to
provide a simpler and less expensive process for producing
pharmaceutical barium sulphate.
Summary of the Invention
In accordance with the present invention, it has
surprisingly been found that a greatly simplified procedure
for producing pharmaceutical barium sulphate is possible by
commencing with a naturally occurring barite ore which contains
individual crys~als of substantially pure barium sulphate.
In other words, the barium ~ulphate within the individual -
crystals is of pharmaceutical purity.
According to thè inventive prccess, this naturally
occurring barite ore containing individual crystals of
~ sub~tantially pure barium sulphate,together with gangue minerals,
:~ i9 first ground to form a finely divided particulate ore
~l material. This finely divided ore is then passed through a
high intensity wet magnetic separator to remove magnetic
particles, leaving a non-magnetic fraction containing barium
-~ sulfate and low specific gravity minerals. The non-magnetic
.. ,~ . .
~,
fraction is subjected to gravity separation and from this
gravity separation a substantially pure barium sulphate fraction
i is obtained. This barium sulphate fraction is then subjected
,~ to leac~ing with sulphuric acid to remove any remaining acid
sOluble impurities and is washed to form a final pharmaceutical
' barium sulphate.
f
The barium sulphate obtained by this procedure
; 30 easily meets all of the USP specifications.
;
f
-- 2

S
DescriPtion of Preferred Embodimen~s
Preparation of Ore
The ore contains, in addition to the individual
crystalls of substantially pure barium sulphate, many other
gangue! minerals. These gangue minerals typically include
iron carbonate, iron oxides, silica and iron silicates.
One example of a typical ore analysis is as follows:
BaS04 74.4%
FeC03 18.6%
SiO2 5.6% ;
Miscellaneous 1.4%
However, it will be appreciated that the gangue minerals
and their proportions can vary greatly in relation to the barium
sulphate and the main consideration is that the lower the amount
of barium sulpbate present in the ore~ the greater amount of ore
; that will hsve to be prepared and processed through the wet
I magnetic ~eparator to obtain a given amount of barium sulphate.
i The ore a~ obtained fxom the mine is preferably sub-
jected to an initial primary grinding with care being taken to
keep the production of fine particle~ to a minimum. This can
conveniently be done, for instance, by means of a ~aw crusher
followed by a gyratory crusher or other means to reduce the
i particles to a convenient working size of, for instance, 1/2 inch.
These ore particles are then subjected to a secondary
grinding, for instance in a ball mill, rod mill or hammer mill,
to produce finely divided particles suitable for feeding to
a high intensity wet magnetic separator. Preferably the
separator feed has a particle size of -35 mesh ~U.S. sieve)
with care being taken to avoid excessive fines.
The size of the particles can be varied depending
on the n~tture of the ore deposits with the concept being to
- 3 -

form particles among which there will be a large number of
individual particles of substantially pure barium sulphate,
Magnetic Separation
The suitably ground ore is subjected to high intensity
wet 1nagnetic separation and a variety of high intensity wet
magnetic separators are known. A particularly suitable machine
is the Jones separator.
The ground ore can be passed through the separator
one or more times to remove as much of the magnetic particles
a~ posslble. The ore will contain particles of varying
s degrees of magnetic susceptability and, for instance, there
may be combined particles of iron carbonate and silica where
the combined particle, due to its iron carbonate content, is
sufficiently magnetic to remove the entire particle. It is
also sometimes desirable to size the feed to the separator
since better recults may be obtained if the feed does not
contain particles of too greatly varying sizes. For instance,
the ore feed to the separator could be divided into three
different size ranges for feeding, e.g. -10 ~ 35; -35 + 65;
-65 + 100 mesh.
During the magnetic separation, the bulk of the
magnetic minerals or combined particles that as a whole
e~hibit some magnetic susceptability are removed. The non-
magnetic fraction at this stage contains primarily barium --
' sulfate and the lighter specific gravity minerals such as
~ quartz, as well as other contaminants such as lead, zinc, etc.
i Gravity Separation
Much of the undesirable material remaining in the
non-magnetic fraction obtained from the magnetic separator
can be removed by gravity separation. A variety of gravity
separators are known and a highly useful one for this purpose
- 4 -

~ iO;~35
is the wet shaking table. Once again, it may be desirable to
brealc the non-magnetic fraction up into quite restricted `
size ranges by screening prior to the gravity separation.
This tends to give a better separation.
The "heavys" end of the table contains predominantly
barium sulfate while the "lights" end contains the gangue.
There may be a fraction removed in between these that, on
completion of the leaching process, does not meet pharmaceutical
specifications, but it has been found that this fraction
normally meets the requirements for a commercial product
known as "Ground White Barite".
Leachin~
The purpose of the leaching step is to eliminate
any remaining soluble impurities f such as soluble barium
salt~ etc. which must be eliminated in order to pass the
specified test. In order to obtain a product meeting USP
specifications, it has been found that the leaching must
be conducted with sulphuric acid.
convenient technique for this is a counter-current
three-stage leach starting with 25% commercial sulphuric acid
; ~ith commercial tap water and three washing steps. Of course,
these steps can be greatly varied depending on the concentration
of the acid used, economics, grade of water, etc.
The product obtained from the leaching step is
1 filtered and washed and can either be made up in plastic bags --
in the ~orm of pre~Mixed dosage units or it may be dried
screened and packaged as a dry powder.
EXAMP~E
An ore sample was obtained from a mine located at
Brookfield, Nova Scotia, Canada. This ore had the following
analysis.
-- 5 --

lO~iOZ35
BaS04
FeC03 18.6%
SiO2 5.6%
Miscellaneous 1.4Z
The ore was reduced in size by means of a jaw crusher
to form particles having a dimension of about 1/2 inch. These ~
particles were then passed through a hammer mill to produce a -
flnely divided ore having particles of -35 mesh.
This finely divided ore was passed through a "Standard
Laboratory Jones High Intensity Wet Magnetic Separator" with a
maximum amperage to coils of 40 amperes to obtain 44% by weight
of a magnetics fraction and 56% by weight of a non-magnetics
fraction. The non-magnetic fraction was screened into the
following ize fractions:
-35 + 60 mesh
! -60 + 150 mesh,~ -150 mesh
Each of the above fractions was subjected to gravity
separation on a wet table no. 11099 ava~lable from Deister
Concentrating Company Inc. and three cuts were made of the
heavys product. In other words, the heavys product was
'1
removed from the wet table as three separate fractions. The
weight distribution of these various fractions is shown in -
3~
-~ Table 1 below:
~ TABLE 1
. _
~; ~ Particle Size -35 + 60 -80 + 150 -150
1 __
, ~ Wet Table Cut C-l C-2 C-3 C-l C-2 C-3 C-l C~2 C-3
% Wt. BaS04
Based on 12.0 4.7 1.91.7 0.9 0.9 2.0 2.6 1.3
Orig. Feed
~ 30 Total BaS04
i (% Wt.) 28.0%
, - 6 -

l~()Z35
The various fractions obtained were then subjected
to leaching with 20~ sulphllric acid solutions using a coun~er
current four stage procedure with analytical grade and commercial
grade sulfuric acid and either tap water or distilled water.
~ach leaching stage was of 30 minutes duration and the leaching
procedures used on the various fractions are set out in Table
2 below:
TABLE 2
Product No.Source Relevant Process Differences
117 Analytical grade ~2S04 and
118 All C-l's distilled water wa~h. All
119 leaching on -150 mesh.
131 C-l, C-2, Analytical grade H2S04 and
132 C-3 tap water wash. Leaching on
133 (-35+60) finely ground.
; 134 C-l, C-2 Analytical grade H2S04 and
135 C-3 tap water wash. Leaching on
136 (-60+150) finely ground.
137 C-l, C-2, Analytical grade H2S04 and
~i 138 C-3 tap water wash. Leaching on
139 (-150) finely ground.
145 C-l Commercial grade acid and tap
146 (-35+60) water. Leaching on -150 mesh.
147 C-l Three stage commercial grade.
148 (-35+60) Last stage analytical with top
water wash. Leaching on -150
mesh.
The above samples were submitted to an independent
testing laboratory for the prescribed tests required under
the USP specifications. The results of these tests are
given in Table 3 below:
:
.~.
' 30
- 7 -
, . ,
.

1~13~5 ~ ~
O cr~ co CQ 0 CO
a) td
~I U~
U~ ~
Fq ..
000000000 ~n 00000 tq
S 0 0 0 0 0 GO 0 0 0 0 0 0 ~0 0 0 ~O
~ ~ 0 ~ ~ ~
o ~ p~ ~ ~ ~ ~ p~ ~ ~ p~ p~ ~ ~ ~ ~ ~ :
s
,
oooooooooooooooo
'C ~ VVVVVVVVVVVVVVVV
E~ ~ :''
~ 00000000,1 0000000
S 0 ~q 0 0 ~ 0 ~n 0 ~ 0 0 0 0 0 0 0
~ ~ ~ 0 ~
U~
iP~! ;~ i~ æ~ ~ i~ i~ i~ ~ K ~ ;P~ K i~
~1 ~1 ~J ~ O C`~ O O O O ~1 ~1 ~ ~1 ~1 ~1
t~l ..............
¢O OOOOOOOOOOOOOOOO
U~ V V V
0
~ . -.
p~0 OOOOOOOOOOOOOOOO
cd~ VVVVVVVVVVVVVVVV
'~ ~
"
O
. æ
~d
~n
. ~ .
:i
.

Representative Drawing

Sorry, the representative drawing for patent document number 1050235 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 1996-03-13
Grant by Issuance 1979-03-13

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
W. J. DENNIS STONE
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Claims 1994-04-22 1 37
Cover Page 1994-04-22 1 15
Abstract 1994-04-22 1 21
Drawings 1994-04-22 1 8
Descriptions 1994-04-22 8 265